Vident Investment Advisory LLC Purchases Shares of 1,284 Allergan PLC. (NYSE:AGN)
Vident Investment Advisory LLC purchased a new stake in shares of Allergan PLC. (NYSE:AGN) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 1,284 shares of the company’s stock, valued at approximately $307,000.
A number of other hedge funds have also bought and sold shares of AGN. Crestwood Advisors Group LLC acquired a new stake in Allergan PLC. during the first quarter valued at about $103,000. Feltz Wealth PLAN Inc. bought a new position in shares of Allergan PLC. during the first quarter valued at $107,000. Enterprise Financial Services Corp boosted its position in shares of Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares during the period. JNBA Financial Advisors boosted its position in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the period. Finally, Webster Bank N. A. boosted its position in shares of Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock valued at $124,000 after buying an additional 123 shares during the period. 84.66% of the stock is owned by institutional investors and hedge funds.
Allergan PLC. (NYSE:AGN) traded down 3.08% during mid-day trading on Friday, reaching $242.65. The company had a trading volume of 3,014,741 shares. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The company has a market capitalization of $81.50 billion, a PE ratio of 7.56 and a beta of 1.16. The firm has a 50-day moving average of $245.21 and a 200 day moving average of $237.12.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period in the prior year, the business posted $3.35 earnings per share. On average, analysts predict that Allergan PLC. will post $16.10 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be given a $0.70 dividend. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.15%. Allergan PLC.’s payout ratio is 9.63%.
AGN has been the topic of several recent analyst reports. Goldman Sachs Group, Inc. (The) cut Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price objective on the stock. in a research note on Wednesday, May 10th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. Zacks Investment Research upgraded Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 target price on the stock in a research note on Tuesday, July 11th. Royal Bank Of Canada set a $279.00 target price on Allergan PLC. and gave the stock a “buy” rating in a research note on Wednesday, April 12th. Finally, Citigroup Inc. lifted their target price on Allergan PLC. to $261.00 and gave the stock a “buy” rating in a research note on Monday, April 24th. Seven research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $274.04.
In related news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.36% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.